Look for Drugs and Conditions

Pegfilgrastim

Pegfilgrastim

It is a pegylated form of the recombinant human granulocyte colonystimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils). The drug is prepared by coupling a 20 kDa polyethylene glycol (PEG) molecule to the N-terminus of the filgrastim protein. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than parent filgrastim (3-4 hours).

Indications

Neutropenia during chemotherapy.


Dosage

SC; 6mg once per chemotherapy cycle.


Contra-Indications

Hypersensitivity to filgrastim.


Special Precautions

Spleen rupture, ARDS, Category C in pregnancy, sickle cell crisis.


Side Effects

Splenomegaly, splenic rupture, sickle cell crises, ARDS, bone pain, pain in extremity, myalgia, arthralgia, headache, nausea, vomiting, constipation, peripheral oedema, inj site reactions, skin rash, urticaria, erythema, flushing, thrombocytopenia, leukocytosis, antibody formation, sweet's syndrome; elevations in uric acid, alkaline phosphatase, lactate dehydrogenase, ALT and AST, Anaphylaxis.


Drug Interactions

Cytotoxic chemotherapy.


Other Brands With Same Generic
Brand Name Manufactured by
NEULASTIM ROCHE
PEGEX PFS EMCURE PHARMA
PREGRAXT-P PREMEDIUM PHARMA
Ad 5